Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Michael Richard Verneris

InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Research 
    Collapse research activities and funding
    K08HL004505     (VERNERIS, MICHAEL R)Apr 6, 2001 - Mar 31, 2006
    Role: Principal Investigator

    R01AI100879     (VERNERIS, MICHAEL R.)May 15, 2013 - Apr 30, 2018
    Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
    Role: Principal Investigator

    R03CA195618     (VERNERIS, MICHAEL R.)Apr 1, 2015 - Mar 31, 2017
    Biomarkers in pediatric versus adult myelodysplastic syndromes
    Role: Principal Investigator

    R01CA196754     (SPECTOR, LOGAN G.)Jul 1, 2015 - Jun 30, 2019
    Genetic epidemiology of hematopoietic cell transplant outcomes
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Touma W, Brunstein CG, Verneris MR, Cao Q, Curtsinger J, Miller JS, Bachanova V. Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Jul 17. PMID: 28729150.
      View in: PubMed
    2. Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A. Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402. Bone Marrow Transplant. 2017 Jun 05. PMID: 28581470.
      View in: PubMed
    3. Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, Müller C, Verneris M, Shaw BE, Pidala J, Oudshorn M, Lee SJ, Spellman SR. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2017 Jun 05. PMID: 28581467.
      View in: PubMed
    4. Angelos MG, Ruh PN, Webber BR, Blum RH, Ryan CD, Bendzick L, Shim S, Yingst AM, Tufa DM, Verneris MR, Kaufman DS. Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood. 2017 Jun 29; 129(26):3428-3439. PMID: 28533309.
      View in: PubMed
    5. Hui S, Brunstein C, Takahashi Y, DeFor T, Holtan SG, Bachanova V, Wilke C, Zuro D, Ustun C, Weisdorf D, Dusenbery K, Verneris MR. Dose Escalation of Total Marrow Irradiation in High-Risk Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1110-1116. PMID: 28396164.
      View in: PubMed
    6. Dourado KM, Baik J, Oliveira VK, Beltrame M, Yamamoto A, Theuer CP, Figueiredo CA, Verneris MR, Perlingeiro RC. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood. 2017 Mar 28. PMID: 28351936.
      View in: PubMed
    7. Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M. Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. Biol Blood Marrow Transplant. 2017 Jun; 23(6):1029-1037. PMID: 28263917.
      View in: PubMed
    8. Mitchell R, Wagner JE, Brunstein C, Cao Q, McKenna DH, Verneris MR. Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2017 May; 23(5):836-839. PMID: 28214595.
      View in: PubMed
    9. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547. PMID: 28177873.
      View in: PubMed
    10. Askar M, Sobecks R, Wang T, Haagenson M, Majhail N, Madbouly A, Thomas D, Zhang A, Fleischhauer K, Hsu K, Verneris M, Lee SJ, Spellman SR, Fernández-Viña M. MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2017 Mar; 23(3):436-444. PMID: 27987385.
      View in: PubMed
    11. He F, Verneris MR, Cooley S, Blazar BR, MacMillan ML, Newell LF, Panoskaltsis-Mortari A, DeFor T, Weisdorf DJ, Holtan SG. Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2017 Feb; 52(2):301-303. PMID: 27869812.
      View in: PubMed
    12. Lu H, Bhoopatiraju S, Wang H, Schmitz NP, Wang X, Freeman MJ, Forster CL, Verneris MR, Linden MA, Hallstrom TC. Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. Oncotarget. 2016 Nov 15; 7(46):76047-76061. PMID: 27738314.
      View in: PubMed
    13. Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani K. A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 Feb 09; 129(6):740-758. PMID: 27821506.
      View in: PubMed
    14. Pritchett JC, Green JS, Thomm AM, Knox KK, Verneris MR, Lund TC. CD4+ T Cells Coexpressing CD134 (OX40) Harbor Significantly Increased Levels of Human Herpesvirus 6B DNA Following Umbilical Cord Blood Transplantation. J Infect Dis. 2016 Dec 15; 214(12):1911-1915. PMID: 27703035.
      View in: PubMed
    15. Goyal RK, Lee SJ, Wang T, Trucco M, Haagenson M, Spellman SR, Verneris M, Ferrell RE. Novel HLA-DP region susceptibility loci associated with severe acute GvHD. Bone Marrow Transplant. 2017 Jan; 52(1):95-100. PMID: 27595289.
      View in: PubMed
    16. Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, Verneris MR, Blazar BR, Miller JS. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res. 2016 Oct 01; 76(19):5696-5706. PMID: 27503932.
      View in: PubMed
    17. Turcotte LM, Yingst A, Verneris MR. Erratum to: "Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction" [Biol Blood Marrow Transplant 2016;22:1159-1166]. Biol Blood Marrow Transplant. 2016 Dec; 22(12):2286. PMID: 27500528.
      View in: PubMed
    18. Kornblit B, Wang T, Lee SJ, Spellman SR, Zhu X, Fleischhauer K, Müller C, Verneris MR, Müller K, Johansen JS, Vindelov L, Garred P. YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome. Bone Marrow Transplant. 2016 Dec; 51(12):1556-1560. PMID: 27427920.
      View in: PubMed
    19. Magome T, Froelich J, Takahashi Y, Arentsen L, Holtan S, Verneris MR, Brown K, Haga A, Nakagawa K, Holter Chakrabarty JL, Giebel S, Wong J, Dusenbery K, Storme G, Hui SK. Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography. Int J Radiat Oncol Biol Phys. 2016 Nov 01; 96(3):679-87. PMID: 27681765.
      View in: PubMed
    20. Ballen K, Woo Ahn K, Chen M, Abdel-Azim H, Ahmed I, Aljurf M, Antin J, Bhatt AS, Boeckh M, Chen G, Dandoy C, George B, Laughlin MJ, Lazarus HM, MacMillan ML, Margolis DA, Marks DI, Norkin M, Rosenthal J, Saad A, Savani B, Schouten HC, Storek J, Szabolcs P, Ustun C, Verneris MR, Waller EK, Weisdorf DJ, Williams KM, Wingard JR, Wirk B, Wolfs T, Young JA, Auletta J, Komanduri KV, Lindemans C, Riches ML. Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep; 22(9):1636-45. PMID: 27343716; PMCID: PMC5008458 [Available on 09/01/17].
    21. Phelan R, Mann E, Napurski C, DeFor TE, Petryk A, Miller WP, Wagner JE, Verneris MR, Smith AR. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transplant. 2016 Oct; 51(10):1369-1375. PMID: 27272448.
      View in: PubMed
    22. Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, Horowitz MM, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 Oct; 101(10):1267-1274. PMID: 27247320.
      View in: PubMed
    23. Arora M, Lee SJ, Spellman SR, Weisdorf DJ, Guan W, Haagenson M, Wang T, Horowitz MH, Verneris MR, Fleischhauer K, Hsu K, Thyagarajan B. Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Aug; 22(8):1531-1532. PMID: 27155583.
      View in: PubMed
    24. Eckfeldt CE, Randall N, Shanley RM, Yohe S, Bejanyan N, Dolan M, Warlick ED, Verneris MR, Brunstein CG, Wagner JE, Weisdorf DJ, Ustun C. Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica. 2016 Aug; 101(8):e348-51. PMID: 27125981; PMCID: PMC4967587.
    25. He F, Warlick E, Miller JS, MacMillan M, Verneris MR, Cao Q, Weisdorf D. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant. 2016 Aug; 51(8):1107-12. PMID: 27064686; PMCID: PMC4972636 [Available on 10/11/16].
    26. Turcotte LM, Yingst A, Verneris MR. Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction. Biol Blood Marrow Transplant. 2016 Jul; 22(7):1159-66. PMID: 27013015; PMCID: PMC4905800 [Available on 07/01/17].
    27. Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016 Jul 15; 22(14):3440-50. PMID: 26847056; PMCID: PMC4947440 [Available on 07/15/17].
    28. Knorr DA, Wang H, Aurora M, MacMillan ML, Holtan SG, Bergerson R, Cao Q, Weisdorf DJ, Cooley S, Brunstein C, Miller JS, Wagner JE, Blazar BR, Verneris MR. Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 May; 22(5):825-33. PMID: 26806586; PMCID: PMC5015683.
    29. Cichocki F, Verneris MR, Cooley S, Bachanova V, Brunstein CG, Blazar BR, Wagner J, Schlums H, Bryceson YT, Weisdorf DJ, Miller JS. The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer. Curr Top Microbiol Immunol. 2016; 395:225-43. PMID: 26037048.
      View in: PubMed
    30. Wilke C, Holtan SG, Sharkey L, DeFor T, Arora M, Premakanthan P, Yohe S, Vagge S, Zhou D, Holter Chakrabarty JL, Mahe M, Corvo R, Dusenbery K, Storme G, Weisdorf DJ, Verneris MR, Hui S. Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. Radiother Oncol. 2016 Jan; 118(1):65-71. PMID: 26653357; PMCID: PMC4764403 [Available on 01/01/17].
    31. Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016 Feb 25; 127(8):1044-51. PMID: 26563133; PMCID: PMC4768428 [Available on 02/25/17].
    32. Davis ZB, Felices M, Verneris MR, Miller JS. Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J. 2015 Nov-Dec; 21(6):486-91. PMID: 26588681; PMCID: PMC4763946.
    33. Turcotte LM, Verneris MR. Is It Better to Be Rich or Relaxed? Sociobiology Meets Bone Marrow Transplant. Clin Cancer Res. 2016 Jan 01; 22(1):6-8. PMID: 26482045; PMCID: PMC4830263 [Available on 01/01/17].
    34. Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, Brunstein C, Wagner JE, Verneris MR, Weisdorf D. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015 Oct; 90(10):892-6. PMID: 26149534; PMCID: PMC4579006 [Available on 10/01/16].
    35. Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan ML, Ustun C, Verneris MR, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):487-92. PMID: 26431630; PMCID: PMC4753126 [Available on 03/01/17].
    36. Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, Verneris MR, Bryceson YT, Weisdorf DJ, Miller JS. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016 Feb; 30(2):456-63. PMID: 26416461; PMCID: PMC4740203.
    37. Ahn YO, Weeres MA, Neulen ML, Choi J, Kang SH, Heo DS, Bergerson R, Blazar BR, Miller JS, Verneris MR. Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation. Eur J Immunol. 2015 Aug; 45(8):2335-42. PMID: 26046454; PMCID: PMC4595159.
    38. Verneris MR, Lee SJ, Ahn KW, Wang HL, Battiwalla M, Inamoto Y, Fernandez-Vina MA, Gajewski J, Pidala J, Munker R, Aljurf M, Saber W, Spellman S, Koreth J. HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1783-9. PMID: 26055300; PMCID: PMC4568127 [Available on 10/01/16].
    39. Davis ZB, Cooley SA, Cichocki F, Felices M, Wangen R, Luo X, DeFor TE, Bryceson YT, Diamond DJ, Brunstein C, Blazar BR, Wagner JE, Weisdorf DJ, Horowitz A, Guethlein LA, Parham P, Verneris MR, Miller JS. Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1653-62. PMID: 26055301; PMCID: PMC4557961.
    40. Sobecks RM, Wang T, Askar M, Gallagher MM, Haagenson M, Spellman S, Fernandez-Vina M, Malmberg KJ, Müller C, Battiwalla M, Gajewski J, Verneris MR, Ringdén O, Marino S, Davies S, Dehn J, Bornhäuser M, Inamoto Y, Woolfrey A, Shaw P, Pollack M, Weisdorf D, Milller J, Hurley C, Lee SJ, Hsu K. Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1589-96. PMID: 25960307; PMCID: PMC4537837.
    41. Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. 2015 Mar 15; 21(6):1267-72. PMID: 25770294; PMCID: PMC4360883.
    42. Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1029-36. PMID: 25759146; PMCID: PMC4426052.
    43. Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30; 371(18):1685-94. PMID: 25354103; PMCID: PMC4257059.
    44. Takahashi Y, Vagge S, Agostinelli S, Han E, Matulewicz L, Schubert K, Chityala R, Ratanatharathorn V, Tournel K, Penagaricano JA, Florian S, Mahe MA, Verneris MR, Weisdorf DJ, Corvo R, Dusenbery KE, Storme G, Hui SK. Multi-institutional feasibility study of a fast patient localization method in total marrow irradiation with helical tomotherapy: a global health initiative by the international consortium of total marrow irradiation. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):30-8. PMID: 25442340; PMCID: PMC4385424.
    45. Verneris MR, Miller JS. KIR B or not to be?...that is the question for ALL. Blood. 2014 Oct 23; 124(17):2623-4. PMID: 25342666; PMCID: PMC4208277.
    46. Ross JA, Tolar J, Spector LG, DeFor T, Lund TC, Weisdorf DJ, Langer E, Hooten AJ, Thyagarajan B, Gleason MK, Wagner JE, Robien K, Verneris MR. An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):81-8. PMID: 25300867; PMCID: PMC4272903.
    47. Mitchell R, Wagner JE, Brunstein CG, Cao Q, McKenna DH, Lund TC, Verneris MR. Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):50-4. PMID: 25262882; PMCID: PMC4378826.
    48. Felices M, Ankarlo DE, Lenvik TR, Nelson HH, Blazar BR, Verneris MR, Miller JS. Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. J Immunol. 2014 Oct 01; 193(7):3344-54. PMID: 25172483; PMCID: PMC4170052.
    49. Weeres MA, Robien K, Ahn YO, Neulen ML, Bergerson R, Miller JS, Verneris MR. The effects of 1,25-dihydroxyvitamin D3 on in vitro human NK cell development from hematopoietic stem cells. J Immunol. 2014 Oct 01; 193(7):3456-62. PMID: 25149465; PMCID: PMC4363084.
    50. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, Weigel BJ, Verneris MR, Miller JS. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014 Sep; 89(9):889-95. PMID: 24891274; PMCID: PMC4134715.
    51. Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant. 2014 Aug; 49(8):1029-35. PMID: 24887379; PMCID: PMC4768798.
    52. Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: 24816582; PMCID: PMC4099265.
    53. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014 Jun 19; 123(25):3855-63. PMID: 24719405; PMCID: PMC4064329.
    54. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014 May 08; 123(19):3016-26. PMID: 24652987; PMCID: PMC4014844.
    55. Sengsayadeth S, Wang T, Lee SJ, Haagenson MD, Spellman S, Fernandez Viña MA, Muller CR, Verneris MR, Savani BN, Jagasia M. Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2014 Jun; 20(6):900-3. PMID: 24631737; PMCID: PMC4034271.
    56. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014 Apr; 26(2):161-72. PMID: 24618042; PMCID: PMC3984606.
    57. Gossai N, Verneris MR, Karras NA, Gorman MF, Patel NJ, Burke MJ. A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD). Bone Marrow Transplant. 2014 Mar; 49(3):440-2. PMID: 24317126.
      View in: PubMed
    58. Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR. Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014 Feb; 49(2):174-8. PMID: 24185590.
      View in: PubMed
    59. Sawitzki B, Brunstein C, Meisel C, Schumann J, Vogt K, Appelt C, Curtsinger JM, Verneris MR, Miller JS, Wagner JE, Blazar BR. Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. Biol Blood Marrow Transplant. 2014 Feb; 20(2):173-82. PMID: 24184334; PMCID: PMC3946612.
    60. Takahashi Y, Verneris MR, Dusenbery KE, Wilke CT, Storme G, Weisdorf DJ, Hui SK. Peripheral dose heterogeneity due to the thread effect in total marrow irradiation with helical tomotherapy. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):832-9. PMID: 24011657; PMCID: PMC3805769.
    61. Burke MJ, Burns L, Linden MA, Lindgren B, Verneris MR, Weisdorf D, Ustun C. How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey. Am J Hematol. 2013 Sep; 88(9):826-7. PMID: 23737091; PMCID: PMC3772519.
    62. Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013 Jul 15; 19(14):3844-55. PMID: 23690482; PMCID: PMC3715574.
    63. Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013 May; 28(4):274-82. PMID: 23611188; PMCID: PMC4209492.
    64. Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1021-5. PMID: 23567175; PMCID: PMC3712759.
    65. Aldoss O, Gruenstein DH, Bass JL, Steinberger J, Zhang Y, Defor TE, Tolar J, Verneris MR, Orchard PJ. Pericardial effusion after pediatric hematopoietic cell transplant. Pediatr Transplant. 2013 May; 17(3):294-9. PMID: 23464863.
      View in: PubMed
    66. Ahn YO, Blazar BR, Miller JS, Verneris MR. Lineage relationships of human interleukin-22-producing CD56+ ROR?t+ innate lymphoid cells and conventional natural killer cells. Blood. 2013 Mar 21; 121(12):2234-43. PMID: 23327921; PMCID: PMC3606063.
    67. Verneris MR. Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. Hematology Am Soc Hematol Educ Program. 2013; 2013:335-41. PMID: 24319201; PMCID: PMC4020013.
    68. Smith AR, Christiansen EC, Wagner JE, Cao Q, MacMillan ML, Stefanski HE, Trotz BA, Burke MJ, Verneris MR. Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. Pediatr Blood Cancer. 2013 Apr; 60(4):705-10. PMID: 23152304; PMCID: PMC3668778.
    69. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Anasetti C, Weisdorf D, Miller JS. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012 Nov 15; 189(10):5082-8. PMID: 23077239; PMCID: PMC3490031.
    70. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012 Dec; 11(12):2674-84. PMID: 23075808; PMCID: PMC3519950.
    71. Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR. Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):138-42. PMID: 22960388; PMCID: PMC3530019.
    72. Karras NA, Weeres M, Sessions W, Xu X, Defor T, Young JA, Stefanski H, Brunstein C, Cooley S, Miller JS, Blazar BR, Wagner JE, Verneris MR. A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant. 2013 Jan; 19(1):109-16. PMID: 22940056; PMCID: PMC3631587.
    73. Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ. Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biol Blood Marrow Transplant. 2012 Jun; 18(6):963-8. PMID: 22430088; PMCID: PMC3631589.
    74. Verneris M, Wagner JE. The epic race to immune reconstitution. Biol Blood Marrow Transplant. 2012 Apr; 18(4):493-4. PMID: 22338627.
      View in: PubMed
    75. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, Niki T, Hirashima M, Blazar BR, Miller JS. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood. 2012 Mar 29; 119(13):3064-72. PMID: 22323453; PMCID: PMC3321868.
    76. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Vergès S, Lanier LL, Weisdorf D, Miller JS. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012 Mar 15; 119(11):2665-74. PMID: 22180440; PMCID: PMC3311280.
    77. Wenner CA, Martzen MR, Lu H, Verneris MR, Wang H, Slaton JW. Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. Int J Oncol. 2012 Apr; 40(4):905-13. PMID: 22159900; PMCID: PMC3584555.
    78. Warlick ED, DeFor T, Blazar BR, Burns L, Verneris MR, Ustun C, Weisdorf DJ, Miller JS. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Mar; 18(3):480-6. PMID: 22155141; PMCID: PMC4107638.
    79. Dezell SA, Ahn YO, Spanholtz J, Wang H, Weeres M, Jackson S, Cooley S, Dolstra H, Miller JS, Verneris MR. Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods. Biol Blood Marrow Transplant. 2012 Apr; 18(4):536-45. PMID: 22155502; PMCID: PMC3303970.
    80. Honebrink T, Dayton V, Burke MJ, Larsen K, Cao Q, Brunstein C, Weisdorf D, Miller JS, Wagner JE, Verneris MR. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun; 18(6):930-6. PMID: 22108570; PMCID: PMC4378716.
    81. Rizwan R, Levine JE, Defor T, Ferarra JL, Weisdorf DJ, Blazar BR, Verneris MR. Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation. Am J Hematol. 2011 Oct; 86(10):879-82. PMID: 21922528; PMCID: PMC3446845.
    82. Ramirez P, Wagner JE, DeFor TE, Blazar BR, Verneris MR, Miller JS, McKenna DH, Weisdorf DJ, McGlave PB, Brunstein CG. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 2012 Jun; 47(6):799-803. PMID: 21946383; PMCID: PMC3590908.
    83. Burke MJ, Lindgen B, Verneris MR. Treatment of relapsed acute lymphoblastic leukemia: approaches used by pediatric oncologists and bone marrow transplant physicians. Pediatr Blood Cancer. 2012 Jun; 58(6):840-5. PMID: 21796765.
      View in: PubMed
    84. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, Weisdorf DJ, Miller JS. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood. 2011 Sep 08; 118(10):2784-92. PMID: 21757615; PMCID: PMC3172795.
    85. Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011 May 12; 117(19):5261-3. PMID: 21403127; PMCID: PMC3109547.
    86. Tang Q, Ahn YO, Southern P, Blazar BR, Miller JS, Verneris MR. Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue. Blood. 2011 Apr 14; 117(15):4052-5. PMID: 21310921; PMCID: PMC3087531.
    87. Grzywacz B, Kataria N, Kataria N, Blazar BR, Miller JS, Verneris MR. Natural killer-cell differentiation by myeloid progenitors. Blood. 2011 Mar 31; 117(13):3548-58. PMID: 21173117; PMCID: PMC3072878.
    88. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1025-32. PMID: 21047561; PMCID: PMC4082980.
    89. Beck JC, Cao Q, Trotz B, Smith AR, Weigel BJ, Verneris MR, Burke MJ. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant. 2011 Jul; 46(7):950-5. PMID: 20856210.
      View in: PubMed
    90. Burke MJ, Vogel RI, Janardan SK, Brunstein C, Smith AR, Miller JS, Weisdorf D, Wagner JE, Verneris MR. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Jun; 17(6):831-40. PMID: 20831896; PMCID: PMC3412271.
    91. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA, Verneris MR, Appelbaum FR, Wagner JE, Delaney C. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010 Nov 25; 116(22):4693-9. PMID: 20686119; PMCID: PMC2996124.
    92. Verneris MR, Burke MJ. Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. Curr Hematol Malig Rep. 2010 Jul; 5(3):157-62. PMID: 20446122.
      View in: PubMed
    93. Ahn YO, Weigel B, Verneris MR. Killing the killer: natural killer cells to treat Ewing's sarcoma. Clin Cancer Res. 2010 Aug 01; 16(15):3819-21. PMID: 20554750.
      View in: PubMed
    94. Smith AR, Gulbahce E, Burke MJ, Cao Q, Macmillan ML, Tolar J, Orchard PJ, Blazar BR, Baker KS, Wagner JE, Verneris MR. Lower leukemia relapse in pediatric patients with pulmonary cytolytic thrombi following allogeneic transplant. Bone Marrow Transplant. 2011 Mar; 46(3):368-71. PMID: 20548337; PMCID: PMC3556271.
    95. Beck JC, Verneris MR. The TREC to less CMV after UCBT. Blood. 2010 May 20; 115(20):4009-10. PMID: 20489061.
      View in: PubMed
    96. Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM. Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1237-44. PMID: 20302960; PMCID: PMC2904410.
    97. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant. 2010 May; 16(5):612-21. PMID: 20139023; PMCID: PMC2854246.
    98. Verneris MR, Wagner JE. UCB and atmospheric noise. Blood. 2010 Jan 28; 115(4):754-5. PMID: 20110431.
      View in: PubMed
    99. Verneris MR, Grupp SA. Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time? J Clin Oncol. 2010 Feb 20; 28(6):909-10. PMID: 20085932.
      View in: PubMed
    100. Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010; 651:61-77. PMID: 20686960.
      View in: PubMed
    101. Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010 Jan; 54(1):138-43. PMID: 19693941; PMCID: PMC4111794.
    102. Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2009 Dec 15; 53(7):1289-94. PMID: 19731318.
      View in: PubMed
    103. Anderson E, Grzywacz B, Wang H, Wang T, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR. Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. Blood. 2009 Nov 19; 114(21):4753-4; author reply 4754-5. PMID: 19965715.
      View in: PubMed
    104. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol. 2009 Oct; 147(2):185-91. PMID: 19796267; PMCID: PMC2770803.
    105. Beck JC, Wagner JE, DeFor TE, Brunstein CG, Schleiss MR, Young JA, Weisdorf DH, Cooley S, Miller JS, Verneris MR. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010 Feb; 16(2):215-22. PMID: 19786112; PMCID: PMC2819578.
    106. Smith AR, Baker KS, Defor TE, Verneris MR, Wagner JE, Macmillan ML. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1086-93. PMID: 19660721.
      View in: PubMed
    107. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 05; 114(19):4293-9. PMID: 19706886; PMCID: PMC2774557.
    108. Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Aug 01; 27(22):3634-41. PMID: 19581540; PMCID: PMC2720079.
    109. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood. 2009 Jun 11; 113(24):6094-101. PMID: 19365083; PMCID: PMC2699231.
    110. Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, DeFor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood. 2009 May 28; 113(22):5628-34. PMID: 19329778; PMCID: PMC2689057.
    111. Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Bone Marrow Transplant. 2009 Aug; 44(3):169-74. PMID: 19204709.
      View in: PubMed
    112. Hui SK, Verneris MR, Froelich J, Dusenbery K, Welsh JS. Multimodality image guided total marrow irradiation and verification of the dose delivered to the lung, PTV, and thoracic bone in a patient: a case study. Technol Cancer Res Treat. 2009 Feb; 8(1):23-8. PMID: 19166239.
      View in: PubMed
    113. Harvey SB, Zhang Y, Wilson-Grady J, Monkkonen T, Nelsestuen GL, Kasthuri RS, Verneris MR, Lund TC, Ely EW, Bernard GR, Zeisler H, Homoncik M, Jilma B, Swan T, Kellogg TA. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res. 2009 Feb; 8(2):603-12. PMID: 19055479.
      View in: PubMed
    114. Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood. 2009 Mar 26; 113(13):2902-5. PMID: 19179301.
      View in: PubMed
    115. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, Blazar BR, Wagner JE. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009 Mar 12; 113(11):2410-5. PMID: 18997171; PMCID: PMC2656268.
    116. Tang Q, Grzywacz B, Wang H, Kataria N, Cao Q, Wagner JE, Blazar BR, Miller JS, Verneris MR. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol. 2008 Oct 01; 181(7):4507-15. PMID: 18802053; PMCID: PMC2614673.
    117. Burke MJ, Trotz B, Luo X, Baker KS, Weisdorf DJ, Wagner JE, Verneris MR. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone Marrow Transplant. 2009 Jan; 43(2):107-13. PMID: 18776928.
      View in: PubMed
    118. Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):467-83. PMID: 18790450; PMCID: PMC2615405.
    119. Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transplant. 2008 Jun; 14(6):685-92. PMID: 18489994.
      View in: PubMed
    120. Grupp SA, Verneris M, Sondel PM, Cooper LJ. Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):33-43. PMID: 18162219; PMCID: PMC2888484.
    121. Jacobson PA, Rydhom N, Huang J, Baker KS, Verneris MR. High-unbound mycophenolic acid concentrations in an infant on peritoneal dialysis following hematopoietic cell transplant. Bone Marrow Transplant. 2007 Nov; 40(9):911-2. PMID: 17724439.
      View in: PubMed
    122. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, Defor T, Blazar BR. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007 Oct 01; 110(7):2761-3. PMID: 17579184; PMCID: PMC1988949.
    123. Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, Blazar BR, Cornfield DN, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007 Sep 01; 110(5):1530-9. PMID: 17495133; PMCID: PMC1975839.
    124. Verneris MR, Wagner JE. Recent developments in cell-based immune therapy for neuroblastoma. J Neuroimmune Pharmacol. 2007 Jun; 2(2):134-9. PMID: 18040838.
      View in: PubMed
    125. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007 Jun 01; 109(11):5058-61. PMID: 17317850; PMCID: PMC1885526.
    126. Lund TC, Anderson LB, McCullar V, Higgins L, Yun GH, Grzywacz B, Verneris MR, Miller JS. iTRAQ is a useful method to screen for membrane-bound proteins differentially expressed in human natural killer cell types. J Proteome Res. 2007 Feb; 6(2):644-53. PMID: 17269721.
      View in: PubMed
    127. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007 Feb; 21(2):356-9; author reply 359. PMID: 17251901.
      View in: PubMed
    128. Hui SK, Verneris MR, Higgins P, Gerbi B, Weigel B, Baker SK, Fraser C, Tomblyn M, Dusenbery K. Helical tomotherapy targeting total bone marrow - first clinical experience at the University of Minnesota. Acta Oncol. 2007; 46(2):250-5. PMID: 17453378.
      View in: PubMed
    129. Peters AM, Blair CK, Verneris MR, Neglia JP, Robison LL, Spector LG, Reaman GH, Felix CA, Ross JA. Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study. Br J Cancer. 2006 Nov 06; 95(9):1274-6. PMID: 17003777; PMCID: PMC2360554.
    130. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006 Dec 01; 108(12):3824-33. PMID: 16902150; PMCID: PMC1895469.
    131. Kasthuri RS, Verneris MR, Ibrahim HN, Jilma B, Nelsestuen GL. Studying multiple protein profiles over time to assess biomarker validity. Expert Rev Proteomics. 2006 Aug; 3(4):455-64. PMID: 16901203.
      View in: PubMed
    132. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant. 2006 Jan; 37(2):175-81. PMID: 16273111.
      View in: PubMed
    133. Karimi M, Cao TM, Baker JA, Verneris MR, Soares L, Negrin RS. Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 2005 Dec 15; 175(12):7819-28. PMID: 16339517.
      View in: PubMed
    134. Nelsestuen GL, Zhang Y, Martinez MB, Key NS, Jilma B, Verneris M, Sinaiko A, Kasthuri RS. Plasma protein profiling: unique and stable features of individuals. Proteomics. 2005 Oct; 5(15):4012-24. PMID: 16130168.
      View in: PubMed
    135. Tan PL, Verneris MR, Charnas LR, Reck SJ, van Burik JA, Blazar BR. Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation. Pediatr Blood Cancer. 2005 Jul; 45(1):74-5. PMID: 15806546.
      View in: PubMed
    136. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karimi M, Karami M, Cao YA, Marina N, Contag CH, Negrin RS. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 2005 Jun 15; 11(12):4561-70. PMID: 15958642.
      View in: PubMed
    137. Peters A, Manivel JC, Dolan M, Gulbahce HE, Baker KS, Verneris MR. Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description. Biol Blood Marrow Transplant. 2005 Jun; 11(6):484-5. PMID: 15931637.
      View in: PubMed
    138. Verneris MR, Karimi M, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004 Apr 15; 103(8):3065-72. PMID: 15070686.
      View in: PubMed
    139. Schrier SL, Centis F, Verneris M, Ma L, Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep. 2003; 8(5):241-5. PMID: 14962357.
      View in: PubMed
    140. Edinger M, Cao YA, Hornig YS, Jenkins DE, Verneris MR, Bachmann MH, Negrin RS, Contag CH. Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer. 2002 Nov; 38(16):2128-36. PMID: 12387838.
      View in: PubMed
    141. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003 Jan 15; 101(2):640-8. PMID: 12393519.
      View in: PubMed
    142. Verneris MR, Baker J, Edinger M, Negrin RS. Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol. 2002 May; 22(3):131-6. PMID: 12078854.
      View in: PubMed
    143. Negrin RS, Edinger M, Verneris M, Cao YA, Bachmann M, Contag ChH. Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence. Ann Hematol. 2002; 81 Suppl 2:S44-5. PMID: 12611073.
      View in: PubMed
    144. Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, Kornacker B, Staratschek-Jox A, Diehl V, Wolf J. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer. 2001 Nov; 94(4):513-9. PMID: 11745437.
      View in: PubMed
    145. Verneris M, McDougall IR, Becton D, Link MP. Thyroid carcinoma after successful treatment of osteosarcoma: a report of three patients. J Pediatr Hematol Oncol. 2001 Jun-Jul; 23(5):312-5. PMID: 11464990.
      View in: PubMed
    146. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001 May 15; 97(10):2923-31. PMID: 11342413.
      View in: PubMed
    147. Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001 Apr 02; 76(3):169-73. PMID: 11306144.
      View in: PubMed
    148. Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant. 2001; 7(1):49-57. PMID: 11215699.
      View in: PubMed
    149. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001; 7(10):532-42. PMID: 11760085.
      View in: PubMed
    150. Verneris MR, Kornacker M, Mailänder V, Negrin RS. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000 Aug; 49(6):335-45. PMID: 10946816.
      View in: PubMed
    151. Verneris MR, Tuel L, Seibel NL. Pediatric HIV infection and chronic myelogenous leukemia. Pediatr AIDS HIV Infect. 1995 Oct; 6(5):292-4. PMID: 11361394.
      View in: PubMed
    Verneris's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)